DCE-MRI changes in tumour vasculature with Avastin & Interferon in RCC

• Research type

  Research Study

• Full title

  Dynamic contrast enhanced MRI (DCE-MRI) assessment of the vascular changes induced with bevacizumab alone and in combination with interferon-a in patients with advanced renal cell carcinoma

• IRAS ID

  10573

• Contact name

  Paul Nathan

• Sponsor organisation

  East and North Hertfordshire NHS Trust

• Eudract number

  2008-006414-19

• ISRCTN Number

  not known

• Research summary

  Bevacizumab in combination with interferon-alpha has been shown to significantly control advanced renal cell carcinoma (RCC) when compared with interferon-alpha alone.This study will establish whether there is a measurably different effect upon the blood vessels supplying the cancer with bevacizumab on its own or in combination with one of two doses of interferon-alpha.Eligible patients will have advanced clear cell renal cell carcinoma and must not have had any previous anti-cancer drug treatment for their disease. Additionally, their disease must be suitable for dynamic contrast enhanced MRI analysis The effect on blood vessels will be analysed by MRI scans twice before starting the medication and at two and six weeks after. Patients who are deriving benefit from treatment will stay on their therapy until they no longer derive benefit. Markers in the blood which shows an effect on new blood vessels will also be analysed to compare with the changes seen in the MRI scans. This study will also help us to explore the response of the tumour to these treatment schedules and correlate the changes with the markers in the blood which can predict which patient group might respond to these treatments.

• REC name

  London - Fulham Research Ethics Committee

• REC reference

  09/H0711/6

• Date of REC Opinion

  21 Jan 2009

• REC opinion

  Favourable Opinion